Generic Medicine Info
Indications and Dosage
Acute postoperative nonobstructive urinary retention, Acute postpartum nonobstructive urinary retention, Neurogenic atony of the bladder with retention
Adult: Initially, 5-10 mg; repeat the initial dose at hourly intervals until an effective response is achieved or until the Maximum of 50 mg is given. Usual dose: 10-50 mg 3-4 times daily. Dose must be individualised based on response, type and severity of condition.
Should be taken on an empty stomach.
Hyperthyroidism, peptic ulcer, latent or active bronchial asthma; coronary artery disease, recent MI, pronounced bradycardia or hypotension, vasomotor instability; epilepsy, parkinsonism; conditions when increased muscular activity of the gastrointestinal tract or urinary bladder may prove harmful (e.g. following recent urinary bladder surgery, gastrointestinal resection and anastomosis, possible gastrointestinal obstruction); conditions wherein the strength or integrity of the gastrointestinal or bladder wall is questionable; mechanical obstruction of the gastrointestinal and genitourinary tract; bladder neck obstruction, acute inflammatory lesions of the gastrointestinal tract, spastic gastrointestinal disturbances, peritonitis, marked vagotonia.
Special Precautions
Patient with bacteriuria. Pregnancy and lactation.
Adverse Reactions
Significant: Increased risk of reflux infection, particularly if the patient has bacteriuria.
Cardiac disorders: Tachycardia.
Eye disorders: Lacrimation, miosis.
Gastrointestinal disorders: Salivation, nausea, vomiting, abdominal cramps or discomfort, colic, borborygmi, belching, diarrhoea.
General disorders and administration site conditions: Malaise.
Nervous system disorders: Headache, seizure.
Renal and urinary disorders: Urinary urgency.
Respiratory, thoracic and mediastinal disorders: Asthma attack, bronchial constriction.
Skin and subcutaneous tissue disorders: Diaphoresis.
Vascular disorders: Hypotension, flushing.
Parenteral/PO/SC: C
Monitoring Parameters
Evaluate bladder and sphincter adequacy prior to treatment initiation.
Symptoms: Nausea, abdominal discomfort, vomiting, salivation, involuntary defecation and urination, lacrimation, sweating, flushing of the skin, transient dyspnoea, palpitation, bradycardia, peripheral vasodilation resulting in hypertension, transient heart block, and substernal pressure or pain. Management: Supportive treatment. Perform aspiration and gastric lavage. Administer IV, SC, or IM atropine sulfate 2-4 hourly as needed based on response to manage muscarinic effects. Supportive treatment may include diazepam 5-10 mg given via IV, small doses of tubocurarine (with assisted respiration) to control muscle twitching, and oxygen administration.
Drug Interactions
Additive effects and increased toxicity with other cholinergic drugs or anticholinesterase agents (e.g. neostigmine). May cause a critical fall in blood pressure (usually preceded by severe abdominal symptoms) when given with ganglionic blocking agents. Atropine, procainamide, quinidine, epinephrine, and other sympathomimetic amines may antagonise the effects of bethanechol.
Mechanism of Action: Bethanechol, a choline ester, is a quaternary ammonium parasympathomimetic agent that exhibits the muscarinic activity of acetylcholine. It acts by directly stimulating the parasympathetic nervous system, thereby releasing acetylcholine at the nerve endings. It increases bladder muscle tone resulting in contractions which initiate urination. Additionally, it stimulates gastric motility, enhances gastric tone, and restores impaired rhythmic peristalsis.
Onset: Within 30 minutes. Peak effect: Approx 60-90 minutes.
Duration: Approx 1 hour (therapeutic doses); 6 hours (large doses [300-400 mg]).
Absorption: Poorly absorbed from the gastrointestinal tract.
Distribution: Does not cross the blood-brain barrier (at usual therapeutic doses).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2370, Bethanechol. Accessed Mar. 29, 2023.

Store between 15-30°C. Protect from light.
MIMS Class
Other Drugs Acting on the Genito-Urinary System
ATC Classification
N07AB02 - bethanechol ; Belongs to the class of choline esters. Used as parasympathomimetics.
Anon. Bethanechol. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 15/03/2023.

Anon. Bethanechol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 15/03/2023.

Bethanechol Chloride Tablet (Amneal Pharmaceuticals of New York, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 15/03/2023.

Buckingham R (ed). Bethanechol Chloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 15/03/2023.

Joint Formulary Committee. Bethanechol Chloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 15/03/2023.

Myotonine Tablets 25 mg (Glenwood GmbH). MHRA. Accessed 15/03/2023.

Uriflow (PHARMASIA). MIMS Philippines. Accessed 20/03/2023.

Disclaimer: This information is independently developed by MIMS based on Bethanechol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in